Eleven Biotherapeutics Presents Data on Ocular Therapeutics Pipeline at the ARVO 2015 Annual Meeting
Eleven Biotherapeutics, a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, has announced the presentation of data for EBI-031, its novel, protein therapeutic IL-6 inhibitor in preclinical development for diabetic macular edema (DME), at the Association for Research in Vision and Ophthalmology (ARVO) 2015 Annual Meeting. These preclinical pharmacokinetic studies with EBI-031, which have been optimized for intravitreal administration using Eleven’s AMP-Rx technology, confirmed the ability of EBI-031 to potently inhibit IL-6 signaling with extended vitreal retention compared to existing therapies. The Company plans to file an investigational new drug (IND) application with FDA by the end of 2015 for clinical development of EBI-031 in DME.
“We are very encouraged by this preclinical pharmacokinetic data demonstrating that we have successfully achieved the important design criteria necessary for an intravitreal IL-6 antagonist and supporting our development plans for EBI-031 in diabetic macular edema,” said Abbie Celniker, President and CEO of Eleven Biotherapeutics. “Based on these data, including potent inhibition of IL-6 signaling, extended vitreal retention compared to existing therapies and rapid systemic clearance, we plan to file an IND application with the FDA by the end of 2015 for clinical development of EBI-031 in DME.”
In a poster presentation entitled, “Optimized Intravitreal IL-6 Antagonist for the Treatment of Diabetic Macular Edema”, Eleven Biotherapeutics researchersdescribe the preclinical data demonstrating that EBI-031 has successfully achieved key design criteria and optimized drug-like properties necessary for an intravitreal IL-6 antagonist including potent blockade of IL-6 signaling, and pharmacokinetics properties such as extended vitreal retention and rapid systemic clearance. Highlights of the poster include
• Potent blockade of both bound (IL-6/sIL-6Rα complex trans-signaling) and free IL-6 (cis-signaling)
o EBI-031 blocks free IL-6 (cis-signaling) >900 fold more potently than standard of care tocilizumab and unlike tocilizumab, potently inhibits hyper IL-6, a genetic fusion of the IL-6/sIL-6Rα trans-signaling complex
• Slow vitreal clearance compared to existing therapies to support monthly or greater frequency of dosing
o EBI-031 cleared in approximately 10 days compared to aflibercept at approximately 6 days and tocilizumab at approximately 5 days in pharmacokinetic studies performed in New Zealand white rabbits injected IVT bilaterally
• Rapid systemic clearance and low systemic accumulation of molecules that escape the eye to minimize toxicity
o Following IV administration in rabbits, EBI-031 is cleared from systemic circulation approximately two times faster than aflibercept, or tocilizumab, and demonstrated lower systemic accumulation than these agents
• Extended duration of EBI-031 blockade through predictive modeling
o Due to its high potency and long vitreal retention, EBI-031 is predicted to inhibit 95% of IL-6 signaling for >100 days following a single 50 mg/mL IVT injection in humans compared to 10 days for tocilizumab or 60 days for aflibercept
• Efficient penetration of ocular tissues
o EBI-031 molecule detected at high levels in the aqueous, choroid, and retina following IVT administration.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance